{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T03:55:58Z","timestamp":1761710158943,"version":"3.40.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Yunnan Applied Basic Research Projects-Union Foundation","award":["202201AY070001-278"],"award-info":[{"award-number":["202201AY070001-278"]}]},{"name":"Yunnan Province High-level Talents Training Support Plan","award":["Famous Doctors Special Project"],"award-info":[{"award-number":["Famous Doctors Special Project"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s12185-025-03915-3","type":"journal-article","created":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T15:10:59Z","timestamp":1737645059000},"page":"547-552","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Venetoclax and azacitidine in combination with homoharringtonine, cytarabine, and aclarubicin for salvage therapy of relapsed\/refractory T cell acute lymphoblastic leukemia"],"prefix":"10.1007","volume":"121","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0329-9936","authenticated-orcid":false,"given":"Lin-sen","family":"Feng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui-yuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0215-449X","authenticated-orcid":false,"given":"Ai","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng-li","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4802-0292","authenticated-orcid":false,"given":"San-bin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,23]]},"reference":[{"issue":"7","key":"3915_CR1","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36(7):1720\u201348.","journal-title":"Leukemia"},{"key":"3915_CR2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023022920","author":"P P\u00f6l\u00f6nen","year":"2024","unstructured":"P\u00f6l\u00f6nen P, Mullighan CG, Teachey DT. Classification and risk stratification in T-lineage acute lymphoblastic leukemia. Blood. 2024. https:\/\/doi.org\/10.1182\/blood.2023022920.","journal-title":"Blood"},{"key":"3915_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02395-4","author":"SR Rheingold","year":"2024","unstructured":"Rheingold SR, Bhojwani D, Ji L, et al. Determinants of survival after first relapse of acute lymphoblastic leukemia: a children\u2019s oncology group study. Leukemia. 2024. https:\/\/doi.org\/10.1038\/s41375-024-02395-4.","journal-title":"Leukemia"},{"issue":"3","key":"3915_CR4","doi-asserted-by":"publisher","first-page":"e142","DOI":"10.1016\/S1470-2045(19)30031-2","volume":"20","author":"DT Teachey","year":"2019","unstructured":"Teachey DT, Pui CH. Comparative features and outcomes between paediatric T-cell and B-cell acute lymphoblastic leukaemia. Lancet Oncol. 2019;20(3):e142\u201354.","journal-title":"Lancet Oncol"},{"issue":"4","key":"3915_CR5","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1002\/hon.2910","volume":"39","author":"JM Ribera","year":"2021","unstructured":"Ribera JM, Morgades M, Genesc\u00e0 E, et al. Outcomes and prognostic factors of adults with refractory or relapsed T-cell acute lymphoblastic leukemia included in measurable residual disease-oriented trials. Hematol Oncol. 2021;39(4):529\u201338.","journal-title":"Hematol Oncol"},{"issue":"11","key":"3915_CR6","doi-asserted-by":"publisher","first-page":"3186","DOI":"10.1002\/cncr.23919","volume":"113","author":"S O\u2019Brien","year":"2008","unstructured":"O\u2019Brien S, Thomas D, Ravandi F, et al. Outcome of adults with acute lymphocytic leukemia after second salvage therapy. Cancer. 2008;113(11):3186\u201391.","journal-title":"Cancer"},{"issue":"8","key":"3915_CR7","doi-asserted-by":"publisher","first-page":"563","DOI":"10.6004\/jnccn.2024.0051","volume":"22","author":"B Shah","year":"2024","unstructured":"Shah B, Mattison RJ, Abboud R, et al. acute lymphoblastic leukemia, version 2.2024, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2024;22(8):563\u201376.","journal-title":"J Natl Compr Cancer Netw"},{"key":"3915_CR8","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: pediatric acute lymphoblastic leukemia. Version 1. 2025. Plymouth Meeting, PA: National Comprehensive Cancer Network. 2024. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1496"},{"issue":"5","key":"3915_CR9","doi-asserted-by":"publisher","first-page":"417","DOI":"10.3760\/cma.j.cn121090-20240319-00102","volume":"45","author":"Hematology Oncology Committee, Chinese Anti-Cancer Association; Leukemia & Lymphoma Group, Chinese Society of Hematology, Chinese Medical Association","year":"2024","unstructured":"Hematology Oncology Committee, Chinese Anti-Cancer Association; Leukemia & Lymphoma Group, Chinese Society of Hematology, Chinese Medical Association. Chinese guideline for diagnosis and treatment of adult acute lymphoblastic leukemia (2024). Chin J Hematol. 2024;45(5):417\u201329. https:\/\/doi.org\/10.3760\/cma.j.cn121090-20240319-00102. (In Chinese).","journal-title":"Chin J Hematol"},{"issue":"5","key":"3915_CR10","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3760\/cma.j.issn.0253-2727.2023.05.001","volume":"44","author":"Hematological Oncology Committee of China Anti-Cancer Association; Chinese Society of Hematology, Chinese Medical Association; Chinese Working Group for T Cell Lymphoma, Hematological Oncology Committee of China Anti-Cancer Association","year":"2023","unstructured":"Hematological Oncology Committee of China Anti-Cancer Association; Chinese Society of Hematology, Chinese Medical Association; Chinese Working Group for T Cell Lymphoma, Hematological Oncology Committee of China Anti-Cancer Association. The consensus of the diagnosis and treatment of adult T-cell lymphoblastic lymphoma in China (2023). Chin J Hematol. 2023;44(5):353\u20138. https:\/\/doi.org\/10.3760\/cma.j.issn.0253-2727.2023.05.001. (In Chinese).","journal-title":"Chin J Hematol"},{"issue":"12","key":"3915_CR11","doi-asserted-by":"publisher","first-page":"977","DOI":"10.3760\/cma.j.issn.0253-2727.2023.12.002","volume":"44","author":"The Society of Blood Disease Translational Medicine of China Anti-Cancer Association; Lymphoma Group, Chinese Society of Hematology, Chinese Medical Association; Hematology Committee of China Medical Women\u2019s Association","year":"2023","unstructured":"The Society of Blood Disease Translational Medicine of China Anti-Cancer Association; Lymphoma Group, Chinese Society of Hematology, Chinese Medical Association; Hematology Committee of China Medical Women\u2019s Association. Chinese expert consensus on diagnosis and treatment of adult early T cell precursor acute lymphoblastic leukemia (2023). Chin J Hematol. 2023;44(12):977\u201382. https:\/\/doi.org\/10.3760\/cma.j.issn.0253-2727.2023.12.002. (In Chinese).","journal-title":"Chin J Hematol"},{"issue":"10","key":"3915_CR12","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1038\/s41409-023-02045-w","volume":"58","author":"W Guo","year":"2023","unstructured":"Guo W, Cao Y, Liu J, et al. Chidamide maintenance therapy in high-risk T-ALL\/T-LBL after allo-HSCT: a prospective, single-center, single-arm study. Bone Marrow Transpl. 2023;58(10):1163\u20136.","journal-title":"Bone Marrow Transpl"},{"issue":"4","key":"3915_CR13","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1002\/hon.2051","volume":"31","author":"SL Xue","year":"2013","unstructured":"Xue SL, Cui HX, Zou JY, et al. Low-dose cytarabine and aclarubicin combined with granulocyte colony-stimulating factor for the treatment of relapsed or primary refractory acute lymphocytic leukemia: a retrospective study of 25 Chinese patients. Hematol Oncol. 2013;31(4):206\u201312.","journal-title":"Hematol Oncol"},{"issue":"3","key":"3915_CR14","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.leukres.2015.01.003","volume":"39","author":"L Liu","year":"2015","unstructured":"Liu L, Jiao W, Zhang Y, Qu Q, Li X, Wu D. Efficacy of low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) compared to hyper-CVAD regimen as salvage chemotherapy in relapsed\/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia. Leuk Res. 2015;39(3):323\u20138.","journal-title":"Leuk Res"},{"issue":"11","key":"3915_CR15","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/j.leukres.2015.08.013","volume":"39","author":"X Li","year":"2015","unstructured":"Li X, Liu L, Zhang Y, et al. Efficacy of cytarabine, aclarubicin and granulocyte colony-stimulating factor (CAG) regimen compared to FLAG regimen for adult patients with relapsed\/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia. Leuk Res. 2015;39(11):1201\u20136.","journal-title":"Leuk Res"},{"issue":"7","key":"3915_CR16","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/S1470-2045(13)70152-9","volume":"14","author":"J Jin","year":"2013","unstructured":"Jin J, Wang JX, Chen FF, et al. Homoharringtonine-based induction regimens for patients with de-novo acute myeloid leukaemia: a multicentre, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2013;14(7):599\u2013608.","journal-title":"Lancet Oncol"},{"issue":"1","key":"3915_CR17","doi-asserted-by":"publisher","first-page":"2343604","DOI":"10.1080\/16078454.2024.2343604","volume":"29","author":"H He","year":"2024","unstructured":"He H, Wen X, Zheng H. Efficacy and safety of venetoclax-based combination therapy for previously untreated acute myeloid leukemia: a meta-analysis. Hematology. 2024;29(1):2343604.","journal-title":"Hematology"},{"issue":"4","key":"3915_CR18","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.clml.2019.09.608","volume":"20","author":"G Richard-Carpentier","year":"2020","unstructured":"Richard-Carpentier G, Jabbour E, Short NJ, et al. Clinical experience with venetoclax combined with chemotherapy for relapsed or refractory T-Cell acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk. 2020;20(4):212\u20138.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"9","key":"3915_CR19","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1080\/10428194.2021.1897807","volume":"62","author":"S Arora","year":"2021","unstructured":"Arora S, Vachhani P, Bachiashvili K, Jamy O. Venetoclax with chemotherapy in relapse\/refractory early T-cell precursor acute lymphoblastic leukemia. Leuk Lymphoma. 2021;62(9):2292\u20134.","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"3915_CR20","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s00277-021-04530-y","volume":"101","author":"J Kong","year":"2022","unstructured":"Kong J, Chen N, Li M, et al. Venetoclax and decitabine in refractory TP53-mutated early T-cell precursor acute lymphoblastic leukemia. Ann Hematol. 2022;101(3):697\u20139.","journal-title":"Ann Hematol"},{"issue":"13","key":"3915_CR21","doi-asserted-by":"publisher","first-page":"3300","DOI":"10.1080\/10428194.2021.1957876","volume":"62","author":"CL Wan","year":"2021","unstructured":"Wan CL, Zou JY, Qiao M, et al. Venetoclax combined with azacitidine as an effective and safe salvage regimen for relapsed or refractory T-cell acute lymphoblastic leukemia: a case series. Leuk Lymphoma. 2021;62(13):3300\u20133.","journal-title":"Leuk Lymphoma"},{"issue":"15","key":"3915_CR22","doi-asserted-by":"publisher","first-page":"5327","DOI":"10.1002\/cam4.3079","volume":"9","author":"JJ Qian","year":"2020","unstructured":"Qian JJ, Hu X, Wang Y, et al. CAG regimen for refractory or relapsed adult T-cell acute lymphoblastic leukemia: a retrospective, multicenter, cohort study. Cancer Med. 2020;9(15):5327\u201334.","journal-title":"Cancer Med"},{"issue":"5","key":"3915_CR23","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1002\/hon.2783","volume":"38","author":"T Meng","year":"2020","unstructured":"Meng T, Yao Y, Xu Y, et al. Salvage therapy with decitabine in combination with granulocyte colony-stimulating factor, low-dose cytarabine, and aclarubicin in patients with refractory or relapsed early T-cell precursor acute lymphoblastic leukemia. Hematol Oncol. 2020;38(5):834\u20137.","journal-title":"Hematol Oncol"},{"issue":"2","key":"3915_CR24","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1111\/j.1349-7006.2011.02150.x","volume":"103","author":"M Horinaka","year":"2012","unstructured":"Horinaka M, Yoshida T, Nakata S, et al. Aclarubicin enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis through death receptor 5 upregulation. Cancer Sci. 2012;103(2):282\u20137.","journal-title":"Cancer Sci"},{"issue":"12","key":"3915_CR25","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1182\/blood.2023023400","volume":"144","author":"S Suo","year":"2024","unstructured":"Suo S, Zhao D, Li F, et al. Homoharringtonine inhibits the NOTCH\/MYC pathway and exhibits antitumor effects in T-cell acute lymphoblastic leukemia. Blood. 2024;144(12):1343\u20137.","journal-title":"Blood"},{"key":"3915_CR26","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2024.2400228","author":"Z Yin","year":"2024","unstructured":"Yin Z, Gao Y, Bu X, et al. Homoharringtonine sensitized resistant acute myeloid leukemia cells to venetoclax-induced apoptosis. Leuk Lymphoma. 2024. https:\/\/doi.org\/10.1080\/10428194.2024.2400228.","journal-title":"Leuk Lymphoma"},{"key":"3915_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2024.07.018","author":"S Suo","year":"2024","unstructured":"Suo S, Sun S, Nguyen LXT, et al. Homoharringtonine synergizes with venetoclax in early T\u00a0cell progenitor acute lymphoblastic leukemia: bench and bed. Med. 2024. https:\/\/doi.org\/10.1016\/j.medj.2024.07.018.","journal-title":"Med"},{"issue":"7","key":"3915_CR28","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1007\/s00432-024-05861-9","volume":"150","author":"Z Yin","year":"2024","unstructured":"Yin Z, Yao Z, Chen D, et al. Homoharringtonine may help improve the outcomes of venetoclax and azacitidine in AML1-ETO positive acute myeloid leukemia. J Cancer Res Clin Oncol. 2024;150(7):336.","journal-title":"J Cancer Res Clin Oncol"},{"key":"3915_CR29","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-024-05892-9","author":"Y Dai","year":"2024","unstructured":"Dai Y, Luo L, Wei Z, Cheng P, Luo J, Li J. The clinical efficacy of a daratumumab-based regimen in relapsed\/refractory acute leukemia: a single-center experience. Ann Hematol. 2024. https:\/\/doi.org\/10.1007\/s00277-024-05892-9.","journal-title":"Ann Hematol"},{"key":"3915_CR30","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024493","author":"T Bhatla","year":"2024","unstructured":"Bhatla T, Hogan LMD, Teachey DT, et al. Daratumumab in pediatric relapsed\/refractory acute lymphoblastic leukemia or lymphoblastic lymphoma: DELPHINUS study. Blood. 2024. https:\/\/doi.org\/10.1182\/blood.2024024493.","journal-title":"Blood"},{"issue":"11","key":"3915_CR31","doi-asserted-by":"publisher","first-page":"4831","DOI":"10.1007\/s00277-024-05943-1","volume":"103","author":"MS Bader","year":"2024","unstructured":"Bader MS, Kubetzko S, Sch\u00e4fer BW, et al. Minimal residual disease monitoring by Ig\/TCR gene rearrangements predicts post-transplant relapse and survival in adult patients with acute lymphoblastic leukemia. Ann Hematol. 2024;103(11):4831\u20133.","journal-title":"Ann Hematol"},{"issue":"5","key":"3915_CR32","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.15366","volume":"38","author":"U Ayg\u00fcne\u015f","year":"2024","unstructured":"Ayg\u00fcne\u015f U, Karag\u00fcn B\u015e, \u015ea\u015fmaz I, Antmen AB. The outcome of relapsed childhood acute lymphoblastic leukemia after allogeneic hematopoietic stem-cell transplantations: a single-center experience. Clin Transpl. 2024;38(5):e15366.\u00a0","journal-title":"Clin Transpl"},{"issue":"4","key":"3915_CR33","doi-asserted-by":"publisher","first-page":"789","DOI":"10.3390\/cancers13040789","volume":"13","author":"M Rasche","year":"2021","unstructured":"Rasche M, Steidel E, Zimmermann M, et al. Second relapse of pediatric patients with acute myeloid leukemia: a report on current treatment strategies and outcome of the AML-BFM study group. Cancers (Basel). 2021;13(4):789.\u00a0","journal-title":"Cancers (Basel)"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-03915-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-025-03915-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-03915-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T13:17:45Z","timestamp":1742390265000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-025-03915-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,23]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["3915"],"URL":"https:\/\/doi.org\/10.1007\/s12185-025-03915-3","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"type":"print","value":"0925-5710"},{"type":"electronic","value":"1865-3774"}],"subject":[],"published":{"date-parts":[[2025,1,23]]},"assertion":[{"value":"20 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This retrospective analysis was approved by the Ethics Committee of The Sixth Affiliated Hospital of Kunming Medical University (Approval number: 2024kmykdx6f201). All diagnostic and therapeutic procedures strictly adhered to the Declaration of Helsinki, relevant clinical practice guidelines, and the laws and regulations of the People\u2019s Republic of China. Prior to treatment, all patients and their close relatives signed paper versions of the informed consent forms.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics and informed consent"}}]}}